

Measures

- #84 Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment
- #85 Hepatitis C: HCV Genotype Testing Prior to Treatment
- #87 Hepatitis C: Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Testing Between 4-12 Weeks After Initiation of Treatment
- #130 Documentation of Current Medications in the Medical Record
- #183 Hepatitis C: Hepatitis A Vaccination
- #226 Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
- #390 Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options
- #401 Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis

Reporting Instructions

- (1) Identify patients with the following criteria:
 - Aged 18 years and older on date of encounter
 - Encounter during January 1 - December 31, 2016 with the following:
 - One of the following diagnosis codes indicating Hepatitis C:
B18.2
 - and
 - One of the following patient encounter codes:
99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99341, 99342, 99343, 99344, 99345, 99347, 99348, 99349, 99350, 99406, 99407
- (2) Report all applicable measures within the measures group for at least 20 patients.
 - The majority of the patients reported must be Medicare Part B Fee-for-service (FFS) patients, including Medicare Secondary and Railroad Medicare.
 - For each measure, the measure's clinical performance must be satisfied for at least 1 patient. [Note: An asterisk (*) indicates that the measure's clinical performance is satisfied.]

For additional information or clinical rationale for measures, review the CMS Measure Specification for 2016 PQRS. All measures group Measure Specifications can be found on the NJII Member Portal > Registry > Getting Started section.

Need more information? Connect with NJII PQRS Registry
973-642-4055 • pqrs@njii.com • www.njii.com/pqrs

Patient Information

First Name

Middle Initial

Last Name

Date of Birth

Visit Date

Medical Record Number

Gender

Male

Female

Medicare FFS Patient

Yes

No

Select Measures Performance

(page 1 of 3)

* Recommended clinical performance satisfied

^ Patient is excluded from measure's performance

Select one (1) clinical action for each measure below, where applicable:

#84: Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment

Patients for whom quantitative HCV RNA testing was performed within 12 months prior to initiation of antiviral treatment.

RNA testing performed within 12 months prior to initiation of antiviral treatment and patient started antiviral treatment*

Patient not receiving antiviral treatment for hepatitis C^

RNA testing not performed (No reason documented)

#85: Hepatitis C: HCV Genotype Testing Prior to Treatment

Patients for whom HCV genotype testing was performed within 12 months prior to initiation of antiviral treatment.

Genotype testing performed within 12 months prior to initiation of antiviral treatment and patient started antiviral treatment*

Patient is not receiving antiviral treatment for Hepatitis C^

Genotype testing not performed (No reason documented)

Select Measures Performance

(page 2 of 3)

#87: Hepatitis C: Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Testing Between 4-12 Weeks After Initiation of Treatment

Patients for whom quantitative HCV RNA testing was performed at no greater than 12 weeks from the initiation of antiviral treatment.

RNA testing performed within 4-12 weeks after the initiation of antiviral treatment*

RNA testing not performed (Medical reason documented)^

Patient is not receiving antiviral treatment^

RNA testing not performed (No reason documented)

#130: Documentation of Current Medications in the Medical Record

Eligible professional attests to documenting, updating or reviewing a patient's current medications using all immediate resources available on the date of encounter. This list must include ALL known prescriptions, over-the counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications' name, dosages, frequency and route of administration.

Current medications documented*

Current medications not documented (Patient not eligible)^

Current medications not documented (Reason not given)

#183: Hepatitis C: Hepatitis A Vaccination

Patients who have received at least one injection of hepatitis A vaccine, or who have documented immunity to hepatitis A.

Hepatitis A vaccine received*

Patient has documented immunity to hepatitis A*

Hepatitis A vaccine injection not received (Medical or patient reason documented)^

Hepatitis A vaccine injection not received (No reason documented)

Select Measures Performance

(page 3 of 3)

#226: Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

Patients who were screened for tobacco use at least once within 24 months AND who received tobacco cessation counseling intervention if identified as a tobacco user

Identified as tobacco user and cessation intervention performed*

Screened for tobacco use and identified as non-user of tobacco*

Not screened for tobacco use (Medical reason documented)^

Identified as tobacco user and cessation intervention NOT performed

Not screened for tobacco use (No reason documented)

#390: Hepatitis C: Discussion and Shared Decision Making Surrounding Treatment Options

Patients with whom a physician or other clinician reviewed the range of treatment options appropriate to their genotype and demonstrated a shared decision making approach with the patient.

Discussion documented*

Discussion not documented (Reason documented)^

Discussion not documented (No reason documented)

#401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis

Patients who underwent abdominal imaging with ultrasound, contrast enhanced CT or MRI.

Imaging Performed*

Imaging not performed (Medical reason documented)^

Imaging not performed (No reason documented)

Measure not applicable